Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 September 2021 | Story Nonsindiso Qwabe | Photo Supplied
Dr Samantha Potgieter.

As COVID-19 vaccines continue to be a topical issue in South Africa and indeed in the world itself, the Department of Human Resources held a webinar for the UFS community on 10 September that delved deeper into the questions surrounding the vaccine. 

Dr Samantha Potgieter, infectious disease expert at the Universitas Academic Hospital and affiliated Lecturer in the Department of Internal Medicine at the University of the Free State, addressed some commonly raised concerns about the COVID-19 vaccine and how it affects us.

Dr Potgieter started off by saying that coronaviruses have been causing outbreaks among humans for millennia. While COVID-19 is relatively mild and self-limiting in 80% of patients, 20% of patients are at risk of developing severe disease.
She said before a vaccine could be introduced to a population, it had to go through rigorous testing and clinical trials. Only once safety has been confirmed, it can be released and distributed. 

“This process usually takes about ten years; this is what we are used to. But it has happened much quicker for the COVID-19 vaccine, and I think this is a fact that many people misinterpret – that the evidence might not be that robust, which is certainly not the case. COVID-19 vaccines have gone through all this rigorous testing, thousands of patients had volunteered for trial testing studies. The point is that we already had the technology, vaccination is not something new to humans. So, these preclinical trials were able to happen very quickly, and because of the large number of infections and because the focus of the entire world was on finding a cure, it was a very set process to get these trials through the adequate phases.” 

She said the COVID-19 vaccine was approved by national regulators, manufactured to exacting standards, and only thereafter distributed – as is the case for all drugs released into the market.

How does the vaccine work?

Dr Potgieter said the vaccine works by producing antibodies against the COVID-19 virus. If you are infected with the COVID-19 virus after getting vaccinated, these antibodies bind to the virus and stop it from replicating.

“When you get infected with a disease such as COVID-19, natural antibodies are produced by the immune system to fight the disease. If you get infected again, the immune system will remember how to respond, and quickly destroy the virus. A vaccine can do the same, but without the risk of disease from natural infection. Vaccines work by imitating a bacteria or virus using either mRNA in the case of the COVID-19 vaccine, or a dead or weakened version of the bacteria or virus. The vaccine raises the body’s alarm. It trains the body to recognise and fight the virus. When the body encounters the real-deal virus, it is primed and ready to fight for the body’s health.”

She said South Africa had the mRNA vaccine in the form of the Pfizer vaccine, and the adenoviral vector vaccine in the form of the Johnson & Johnson vaccine.

Why should you get the vaccine?

Dr Potgieter said vaccines are safe and effective, and the most compelling reasons for getting vaccinated are the following:

-To protect yourself from severe disease
-To protect those around you who may be at risk of severe disease
-To restore the social and economic platforms of the country, and the world at large.
She said that while the vaccine does not prevent you from getting COVID-19, it offers better protection against the development of severe disease, and vaccinated people had 50% less chance of spreading the virus.
The most common side effects of the vaccine are the following:
-Pain at the injection site
-Swollen lymph nodes
-Fever
-Fatigue
-Headache
-Myalgia (muscle pain)

“These are indications that the immune system is mounting a response. When it mounts a response, it produces antibodies,” she said.

Answers to commonly asked questions are the following:

1. Can the vaccine alter my DNA?
“No, it goes nowhere near the nucleus of the cell.”

2. What happens when you get COVID in between the first and second doses?
“Some protection is conferred after the first dose, but maximum protection is conferred two weeks after the second dose. Vaccination is still advised.” 

Dr Potgieter said patients who were between vaccinations still show better recovery results than those without.

3. What about natural immunity?
“Natural immunity might confer better protection, but it runs the risk of severe disease. Yes, immunity can be gained through natural immunity, it can be gained through vaccination, and it can certainly be gained by a combination of the two.”

4. What about long-term side effects?
“Serious side effects that cause long-term health problems following any vaccination are very rare, including the COVID-19 vaccination.”

To get the answers to more of your questions, the webinar can be accessed via the following link: https://event.webinarjam.com/go/replay/43/053q6a8vay9a0qa2

News Archive

Research project gives insight into the world of the deaf
2005-11-30

Mr Akach in conversation (using sign language) with his assistant Ms Emily Matabane. Photo: Lacea Loader

UFS research project gives insight into the world of the deaf

The Sign Language Division of the University of the Free State’s (UFS) Department of Afro-Asiatic Studies and Language Practice and Sign Language has signed a bilateral research project with the universities of Ghent and Brussels to write a book on sign language. 

“We want to compare the Belgium and South African sign languages with each other.  The book will be about the deaf telling us about themselves and how they live.  It will also focus on the use of story telling techniques and the grammar used by deaf people.  We want to see if the hand forms and the grammatical markers and other linguistic features that deaf people from these two countries use are the same or not,” said Mr Philemon Akach, lecturer at the UFS Sign Language Division and coordinator of the research.  

According to Mr Akach, the sign language community in South Africa, with about 600 000 deaf people who use South African Sign Language (SASL) as first language, is quite big.  “Over and above the deaf people in South Africa, there are also the non-deaf who use SASL, like the children of deaf parents etc.  This book can therefore be used to teach people about the deaf culture,” he added.

Another of Mr Akach’s achievements is his election as Vice-President of the newly established World Association of Sign Language Interpreters (WASLI).  The association was established earlier this month during a conference in Worcester.

Mr Akach has been actively involved with sign language interpretation since 1986 and has been interpreting at the World Congress of the World Federation of the Deaf (WFD) since 1987.  “My appointment as Vice-President of the WASLI is an emotional one.  I have been involved with deaf people for so long and have been trying to create awareness and obtain recognition for sign language, especially in Africa,” said Mr Akach.  WASLI is affiliated to the WFD.

According to Mr Akach there was no formal structure in the world to support sign language and sign language interpreters.   “Now we have the backup of WASLI and we can convince governments in other African countries and across the world to support deaf people by supporting WASLI and therefore narrow the communication gap between the deaf and the hearing.  My main aim as Vice-President is to endeavour for the recognition of sign language and spoken language interpreters as a profession by governments,” he said. 

According to Mr Akach the formal training of interpreters is of vital importance.  “Anybody who has a deaf person in his/her family and can communicate in sign language can claim that they are an interpreter.  This is not true.  It is tantamount to think that all mother tongue or first language speakers are interpreters.  Likewise students who learn sign language up to whatever level and are fluent in signing, should still join an interpreter’s programme,” he said.

“Sign language interpreting is a profession and should be presented as an academic course alongside other spoken languages.  The UFS has been taking the lead with sign language and spoken language interpretation and was the first university on the African continent to introduce sign language as an academic course,” he said.

“Although sign language has always been an unknown language to young people it has become quite popular in recent years.  This year we had a total of 160 students at the Sign Language Section of the UFS and the numbers seem to increase steadily every year,” he said.

Mr Akach’s assistant, Ms Emily Matabane, is deaf and they communicate in sign language.  Ms Matabane also handles the tutorials with students to give them hands-on experience on how to use sign language.  


Media release
Issued by: Lacea Loader
Media Representative
Tel:   (051) 401-2584
Cell:  083 645 2454
E-mail:  loaderl.stg@mail.uovs.ac.za
30 November 2005

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept